Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival.
Solari V, Borriello L, Turcatel G, Shimada H, Sposto R, Fernandez GE, Asgharzadeh S, Yates EA, Turnbull JE, DeClerck YA. Solari V, et al. Among authors: asgharzadeh s. Cancer Res. 2014 Nov 1;74(21):5999-6009. doi: 10.1158/0008-5472.CAN-13-2513. Epub 2014 Aug 27. Cancer Res. 2014. PMID: 25164011 Free PMC article.
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
Zacharoulis S, Levy A, Chi SN, Gardner S, Rosenblum M, Miller DC, Dunkel I, Diez B, Sposto R, Ji L, Asgharzadeh S, Hukin J, Belasco J, Dubowy R, Kellie S, Termuhlen A, Finlay J. Zacharoulis S, et al. Among authors: asgharzadeh s. Pediatr Blood Cancer. 2007 Jul;49(1):34-40. doi: 10.1002/pbc.20935. Pediatr Blood Cancer. 2007. PMID: 16874765
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller DC, Allen J, Gardner S. Fangusaro J, et al. Among authors: asgharzadeh s. Pediatr Blood Cancer. 2008 Feb;50(2):312-8. doi: 10.1002/pbc.21307. Pediatr Blood Cancer. 2008. PMID: 17668858 Clinical Trial.
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen le B, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, Capasso M, Pawel BR, Devoto M, Hakonarson H, Rappaport EF, Irminger-Finger I, Maris JM. Bosse KR, et al. Among authors: asgharzadeh s. Cancer Res. 2012 Apr 15;72(8):2068-78. doi: 10.1158/0008-5472.CAN-11-3703. Epub 2012 Feb 20. Cancer Res. 2012. PMID: 22350409 Free PMC article.
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC. Asgharzadeh S, et al. J Clin Oncol. 2012 Oct 1;30(28):3525-32. doi: 10.1200/JCO.2011.40.9169. Epub 2012 Aug 27. J Clin Oncol. 2012. PMID: 22927533 Free PMC article.
PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas.
Erdreich-Epstein A, Robison N, Ren X, Zhou H, Xu J, Davidson TB, Schur M, Gilles FH, Ji L, Malvar J, Shackleford GM, Margol AS, Krieger MD, Judkins AR, Jones DT, Pfister SM, Kool M, Sposto R, Asgharzadeh S. Erdreich-Epstein A, et al. Among authors: asgharzadeh s. Clin Cancer Res. 2014 Feb 15;20(4):827-36. doi: 10.1158/1078-0432.CCR-13-2053. Epub 2013 Dec 3. Clin Cancer Res. 2014. PMID: 24300787 Free PMC article.
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Oberthuer A, et al. Among authors: asgharzadeh s. Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17. Clin Cancer Res. 2015. PMID: 25231397
106 results